Impact of the left ventricular mass index on the outcomes of severe aortic stenosis. Issue 24 (6th July 2017)

• Record Type: Journal Article
• Authors: Minamino-Muta, Eri; Kato, Takao; Morimoto, Takeshi; Taniguchi, Tomohiko; Inoko, Moriaki; Haruna, Tetsuya; Izumi, Toshiaki; Miyamoto, Shoichi; Nakane, Eisaku; Sasaki, Kenichi; Funasako, Moritoshi; Ueyama, Koji; Shirai, Shinichi; Kitai, Takeshi; Izumi, Chisato; Nagao, Kazuya; Inada, Tsukasa; Tada, Eiji; Komasa, Akihiro; Ishii, Katsuhisa; Saito, Naritatsu; Sakata, Ryuzo; Minatoya, Kenji; Kimura, Takeshi
• Is Part Of: Heart. Volume 103:Issue 24(2017)
• Page Start: 1992
• Page End: 1999
• Publication Date: 2017-07-06
• Subjects: aortic stenosis; Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/heartjnl-2016-311022
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Objective: To elucidate the factors associated with high left ventricular mass index (LVMI) and to test the hypothesis that high LVMI is associated with worse outcome in severe aortic stenosis (AS). Methods: We analysed 3282 patients with LVMI data in a retrospective multicentre registry enrolling consecutive patients with severe AS in Japan. The management strategy, conservative or initial aortic valve replacement (AVR), was decided by the attending physician. High LVMI was defined as LVMI >115 g/m 2 for males and >95 g/m 2 for females. We compared the risk between normal and high LVMI in the primary outcome measures compromising aortic valve-related death and heart failure hospitalisation. Results: Age was mean 77 (SD 9.6) years and peak aortic jet velocity (Vmax) was 4.1 (0.9) m/s. The factors associated with high LVMI (n=2374) included female, body mass index ≥22, absence of dyslipidemia, left ventricular ejection fraction <50%, Vmax ≥4 m/s, regurgitant valvular disease, hypertension, anaemia and end-stage renal disease. In the conservative management cohort (normal LVMI: n=691, high LVMI: n=1480), the excess adjusted 5-year risk of high LVMI was significant (HR: 1.53, 95% CI 1.26 to 1.85, p<0.001). In the initial AVR cohort (normal LVMI: n=217, high LVMI: n=894), the risk did not differ significantly between the two groups (HR: 0.96, 95% CI 0.60 to 1.55, p=0.88). There was a significant interaction between the initial treatment strategy and the risk of high LVMI (p=0.016). Conclusions: The deleterious impact of high LVMI on outcome was observed in patients managed conservatively, but not observed in patients managed with initial AVR. Trial registration number: UMIN000012140; Post-results.